NEW YORK – BioAI on Monday said it has partnered with Arbele to develop artificial intelligence-based models for colorectal cancer biomarker screening using Arbele's clinical trial data.
The firms aim to use the model to create a companion diagnostic test for Hong Kong-based Arbele's investigational drug programs. Initially, they will develop a prototype machine-learning classifier to quantify CDH17 expression patterns in colorectal cancer samples using hematoxylin- and eosin-stained and immunohistochemistry images with the goal to standardize and improve pathologic assessment of treatment response biomarkers for more effective patient selection in Arbele's therapeutic development programs.
Arbele's lead compound is ARB202, a bispecific antibody targeting CDH17 and CD3, which the company is developing as a treatment for advanced gastrointestinal malignancies in a Phase I clinical trial. In the trial, researchers are evaluating safety, tolerability, pharmacokinetics, and anti-tumor activity of ARB202 in 68 patients with gastrointestinal cancers including colorectal, pancreatic, gastric, liver, and bile duct cancers that have 10 percent or greater expression of CDH17.
In June, BioAI signed another collaboration agreement with Genomic Testing Cooperative to develop AI-based tests supporting the pharmaceutical industry and clinicians.